Executive Chairman and former CEO of Maravai LifeSciences, Inc. Carl Hull, has been reinstated as CEO of the company on an interim basis. Three subsidiaries of Danaher Corporation, two of which previously employed recently-appointed Maravai CEO William “Trey” Martin, III, have filed a lawsuit against Martin and Maravai in the Delaware Court of Chancery alleging that Martin is in breach of a noncompetition agreement. On October 18, 2022, the Court issued a temporary restraining order against Martin prohibiting him from working for Maravai pending a preliminary injunction hearing that is expected to occur later this year.

Mr. Martin has been placed on paid leave pending the outcome of this matter. Under the renewed leadership of Mr. Hull, Maravai will continue to serve its customers, employees, and shareholders.